

(Under Corporate Insolvency Resolution Process)

January 08, 2018

**BSE Limited
Corporate Relationship Department
1st floor, New Trading Ring
Rotunda Building, P J Towers
Dalal Street, Fort
Mumbai - 400 001**

Dear Sir/Madam


In accordance with the requirements of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are pleased to inform that Orchid received the Establishment Inspection Report (EIR) from USFDA based on the successful inspection closure for the Post-marketing Adverse Drug Experience reporting inspection (PADE) conducted at Orchid Towers 313, Valluvar Kottam High Road, Nungambakkam, Chennai Tamil Nadu, India.

The facility was inspected by USFDA in the month of June 2017.

Kindly take the above information on your records.

Thanking you,

Yours faithfully,



L Chandrasekar
Executive VP – Finance & Secretary